Table 2

Neutralization titer against HIV-1 clinical isolates in BALB/c mice

Vaccine groups

Neutralization titer against HIV-1 isolates

XJDC6371

XJDC6431

XJDC0793

CBJB105

CBJB248

020101300

SV145

< 6

< 6

< 6

< 6

< 6

> 12

SV145-10M

> 12

> 24

> 24

> 24

> 24

> 12

SV145M1&2

< 6

> 24

> 24

> 24

> 24

> 24

SV145M1

< 6

> 24

> 24

> 24

> 24

> 24

SV145M2

< 6

> 12

> 12

> 12

> 12

> 12

SV145M3

< 6

< 6

< 6

< 6

> 12

> 12

SV145M4

< 6

< 6

< 6

< 6

> 12

> 12

SV145M5

< 6

< 6

< 6

< 6

< 6

< 6

The neutralization was conducted by using a panel of clinical isolates in PBMCs with 50% inhibitory dose. Gp145-10 M, gp145M1&2, gp145M1 and 145M2 groups could neutralize HIV-1 isolates at the highest titer of 1:24, other than XJDC6371. The single N-glycosylation site deletion in the V1 loop designated as gp145M2 could induce broader neutralizing antibodies against five clinical isolates at a titer of 1:12.

Liu et al. Retrovirology 2010 7:71   doi:10.1186/1742-4690-7-71